Hopkins - MBA Trivia: COVID oral pill

Two years ago, two anti-COVID19 oral pills are ready for use now, namely Molnupiravir from Merck and Paxlovid from Pfizer.

Merck’s Molnupiravir has been approved for emergency use in the UK for the treatment of patients with mild to moderate Covid19 and those at risk of severe illness, including those with obesity, elderly, diabetes or heart disease. The results of clinical trials indicate that the new drug can reduce the risk of hospitalization or death by about half. Paxlovid is developed by Pfizer. Its clinical results show that it can even reduce the risk of hospitalization or death by 85%-89%.

At present, Merck announced its application has been submitted to the U.S. Food and Drug Administration (FDA). Both new pills can effectively fight against variant viruses such as Delta, Gamma, and Mu, and the viruses are also difficult to develop resistance to them. However, it is still unknown when the pandemic will end.

News & Events

Hopkins Joins Sounds of Silence Project

Hopkins was one of the sponsors for the Sound of Silence Project jointly organized by the HK Police Force and HK Correctional Services. The purpose …

UNI Cocktail Reception 2015

To celebrate Prof. William Ruud taking up the 10th Presidency of UNI and the graduates who completed all the hard work and achieved their degree.....

The Pioneer of Summer Study Tours

As early as in 1999, we perceived the value for students in Hong Kong to gain overseas study experience and exposure while enjoying the fun …

Hopkins Training & Education Group
31-33, 1/F, Tower 1, South Seas Center, 75 Mody Road, TST East, Hong Kong
Fax: +852 2332-2390
Whatsapp: +852 9840-8977

Copyright © 2020 Hopkins Training & Education Group         See Our Privacy Policy
Disclaimer: It is a matter of discretion for individual employers to recognize any qualifications to which these courses may lead.